Chao-Lan Yu

Appointment : Professor

Lab：Cancer and Metabolism Research

Education : Ph.D.

University/Nation：Univ. of Michigan, USA

Tel: 3730

E-mail : clyu@mail.cgu.edu.tw

Research website : https://ls.cgu.edu.tw/p/412-1073-12200.php?Lang=zh-tw

Research interests:

·  oncogenes and tumor suppressor genes

·  cancer metabolism and animal models

·  molecular mechanisms of nuclear-mitochondrial crosstalk

·  In vivo metabolic study in mice with glucose/insulin clamp technique

Publications:

Chueh FY, Chang YL, Wu SY, and Yu CL.  May 2020.  Signal transducer and activator of transcription 5a (STAT5a) represses mitochondrial gene expression through direct binding to mitochondrial DNA.  Biochem. Biophys. Res. Commun. 527:974-978.

Wu YH, Chuang LP, Yu CL, Wang SW, Chen HY, Chang YL.  Jun 2019.  Anticoagulant effect of wogonin against tissue factor expression.  Eur. J. Pharmacol. 859:Article 172517

Chang CW, Hsu CY, Hsu J, Ku YC, Liao TC, Lin BT, Liu TL, Lu M, Lu YH, Wang YY, Yen DL, Chang KP, Chen GW, Lee CC, Yu CL.  16 May 2017.  Leijuvant - A revolutionary choice of vaccine helper; Construction of an E. coli-Leishmania shuttle vector.  PLOS Collections: iGEM 2016.

Chang KP, Kolli BK, and the New Light Group (Batchu R, Chen HW, Chow LC, Elliott R, Head J, Fan CK, Hung CH, Ji DD, Lun ZR, Manna L, Matsumoto Y, Ng DP, de Oliveira C, Melo S, Ozbel Y, Ozbilgin A, Reynolds J, Sanjoba C, Shiao SH, Shih NY, Tsai CW, Vicente MG, Barre C, Volf P, Wu YL, Yu CL, Zhou XN).  13 July 2016.  New "light" for one-world approach toward safe and effective control of animal diseases and insect vectors from leishmaniac perspectives.  Parasite Vector 9(1):396.

Yu CL, Jove R, and Turkson J.  September 2016.  Chapter 4: Historical development of STAT3 inhibitors and early results in clinical trials.  Book title: STAT inhibitors in cancer (ISBN: 978-3-319-42947-2).  Series title: Cancer Drug Discovery and Development.  Humana Press.  Pages 69-94.